09. September 2010
Transglutaminase Newsletter September 2010 - New Catalog 2011

18. July 2010
Zedira supports Gordon Conference on "Transglutaminases In Human Disease Processes"

15. April 2010
CHDI Foundation names Zedira as supplier for R&D products in August 2010

17. March 2010
Transglutaminase Newsletter March 2010

03. February 2010
Zedira presents preclinical data at “Development of Therapies for Celiac Disease” conference in New York

01. January 2010
Overview on celiac disease drug development approaches (published in the German patients magazine "DZG-Aktuell" issue 01/2010, article in German)


  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.


  • Pressemitteilung: Dr. Falk Pharma und Zedira geben den Abschluss der Phase 1b-Studie für ZED1227 zur Zöliakie-Therapie bekannt und planen Start der Wirksamkeitsstudie
  • Press release: Dr. Falk Pharma and Zedira announce completion of phase 1b clinical trial of ZED1227 for the treatment of celiac disease and move on to proof of concept study
  • Press Release: Dr. Falk Pharma GmbH and Zedira enter a phase 1b clinical trial for a celiac disease drug
  • Zedira publication: Microbial transglutaminase has a lower deamidation preference than human tissue transglutaminase on a celiac disease relevant wheat gliadin T-cell epitope
  • Press release: Additional subsidy funding for clinical development of a celiac disease drug
  • Pressemitteilung: Zusätzliche Fördermittel für die klinische Entwicklung eines Zöliakie-Medikamentes
  • Press Release: Cooperation between Zedira and Cardiff University - Transglutaminase 6 is the focus of new research into ataxia
  • Press Release: Dr. Falk Pharma and Zedira enter phase I clinical trials for a celiac disease drug
  • Press release: Zedira receives further funding to develop Factor XIIIa-blockers for safe anticoagulation